Market Overview

Morning Market Movers

Related NBIX
US Stock Futures Tumble Ahead Of Durable-Goods Orders, Jobless Claims Data
UPDATE: Morgan Stanley Downgrades Neurocrine Biosciences on Recent Stock Appreciation
Related EPZM
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Epizyme, Transition Therapeutics
Epizyme Up on Milestone Payment from Glaxo - Analyst Blog

Neurocrine Biosciences (NASDAQ: NBIX) jumped 60.40% to $15.66 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.

Epizyme (NASDAQ: EPZM) moved up 55.32% to $31.84 after the company reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.

Verso Paper (NYSE: VRS) rose 31.70% to $4.23 after the company announced its plans to acquire NewPage for $1.4 billion.

Stereotaxis (NASDAQ: STXS) shares jumped 19.26% to $4.77 after the company Stereotaxis completed the clinical trial of Vdrive with V-Loop.

Posted-In: market moversNews Intraday Update Markets Movers

 

Most Popular

Related Articles (NBIX + EPZM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters